Bellevue Asset Management (Switzerland)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$6.81M	Hold	65,000	–	–	1.04%	31
2015 Q3	$6.85M	Hold	65,000	–	–	1.12%	29
2015 Q2	$8.89M	Sell	65,000 -36,000	-36%	-$4.46M	1.23%	27
2015 Q1	$11.4M	Buy	+101,000	New	+$10.7M	1.58%	15

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s BMRN Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its BioMarin Pharmaceuticals (BMRN) position steady in Q4 2015 at 65,000 shares worth $6.81M. The position accounts for 1.04% of the portfolio, ranked #31.

Bellevue Asset Management (Switzerland) first reported a position in BMRN in Q1 2015 and has held it in 4 quarters since. The position peaked at $11.4M in Q1 2015. 389 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Bellevue Asset Management (Switzerland) held 65,000 shares of BioMarin Pharmaceuticals worth $6.81M as of Q4 2015.
Bellevue Asset Management (Switzerland) left its BioMarin Pharmaceuticals share count unchanged in Q4 2015.
BioMarin Pharmaceuticals made up 1.04% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #31 holding.
Bellevue Asset Management (Switzerland) first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
Bellevue Asset Management (Switzerland)'s BioMarin Pharmaceuticals position peaked at $11.4M in Q1 2015.
389 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.